September 29th 2023
The recent study also found that Jardiance for patients with heart failure with preserved ejection fraction could be cost-effective if discounted by 29%.
September 27th 2023
September 21st 2023
ICER: Monoclonal Antibodies Not Cost-Effective in Multiple Sclerosis
December 21st 2022The monoclonal antibodies that treat patients with multiple sclerosis would have to be priced more than 50% lower to meet the common standards of cost-effectiveness, according to the Institute for Clinical and Economic Review.
Inflation Reduction Act and the Impact on Pharmaceutical Pricing and Investment Decisions
November 25th 2022The reference to “maximum fair price” in the act bodes poorly for manufacturers and suggests more of a take-it-or-leave-it situation rather than a negotiation where clinical evidence would be the prevailing factor in determining price.
Employers are Concerned about Specialty Drug Costs
November 3rd 2022Wendy Barnes and Mark Campbell of RxBenefits discuss the company’s survey, which finds employers are curious about solutions to manage both specialty drug spend and the potential volatility that comes with employees who may be diagnosed with cancer and other high-dollar conditions.